Benzimisazo[4,5-f]isoquinolinone derivatives

1. A compound of fomula I:

wherein one of the bond is a double bond, and the other is a single bond;

Q is N or C;

R 1 is attached to the nitrogen atom having the available valence, and is selected om hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, aryl-C 1-3 alkyl, and aryl wherein said akyl, alkenyl, cycloalkyl, and aryl are optionally substituted with one to three groups independently selected from X;

R 2 is a group selected from R 1 ;

R 3 , R 4 , R 6 and R 7 are independently selected from hydrogen, X, C 2-6 alkenyl and C 3-6 cycloalkyl wherein said alkenyl and cycloalkyl are optionally substituted with one to three groups independently selected from X;

R 5 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, Cy, and Cy-C 1-3 alkyl, wherein said alkyl, alkenyl, and Cy are optionally substituted with one to three groups independently selected from X;

Cy is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl;

X is selected from:

halo,

CN,

OR a ,

C 1-6 perfluoroalkyl,

C(O)R a ,

C(O)OR a ,

C(O)NR b R c ,

NR b R c ,

NHR b NHR b ,

NHC(O)R a ,

NHC(O)OR a ,

phenyl wherein phenyl is optionally substituted with one to three groups independently selected from R x ,

C 1-6 alkyl optionally substituted with OH, C 3-7 cycloalkyl, phenyl, or heterocyclyl, wherein phenyl is optionally substituted with one to three groups independently selected from R x , and wherein said heterocyclyl is optionally substituted with one to three groups independently selected from R y ,

heterocyclyl wherein said heterocyclyl is optionally substituted with one to three groups independently selected from R y ,

S(O) n R a , wherein n is 0, 1 or 2 and

SO 2 NHR a ;

R a , R b and R c are independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Cy and Cy-C 1-3 alkyl, wherein Cy is optionally substituted with one to three groups selected from R y ; or

R b and R c together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and

N—R e ;

R e is selected from hydrogen, C 1-6 alkyl, Cy and Cy-C 1-3 alkyl;

R x is selected from halo, phenyl, CN, NO 2 , OH, OC 1-6 alkyl, C 1-6 alkyl, NH 2 , C 1-6 alkyl, N(C 1-6 alkyl) 2 , C(O)C 1-6 alkyl, C(O)OC 1-6 alkyl, C(O)NHC 1-6 alkyl, C(O)N(C 1-6 alkyl) 2 , NHC(O)C 1-6 alkyl;

R y is a group selected from R x , oxo, C 1-6 alkyl substituted with C 3-7 cycloalkyl and C(O)OCH 2 -phenyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R 1 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl and aryl-C 1-3 alkyl wherein alkyl, cycloalkyl and aryl are optionally substituted with one or two groups independently selected from X.

3. A compound of claim 1 wherein R 3 and are R 4 are independently selected from hydrogen, halogen and trifluoromethyl.

4. A compound of claim 1 wherein Q is C and one of R 3 and R 4 is halogen or trifluoromethyl at the 9-position, and the other is H, halogen or trifluoromethyl.

5. A compound of claim 1 wherein R 5 is s lected from C 1-6 alkyl and Cy wherein each is optionally substituted with one to three groups independently selected from X.

6. A compound of claim 1 wherein R 5 is phenyl optionally substituted with one to three groups independently selected from X.

7. A compound of claim 1 wherein Q is C.

8. A compound of claim 1 wherein Q is N.

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.